TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02824562

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention
Description: The intervention group will receive treatment as usual plus a chronic pain self-management program which includes six one-on-one sessions facilitated by a trained interventionist and six group sessions facilitated by a trained interventionist and a peer. A peer is an HIV-infected patient living with chronic pain, who has completed all ten of the one-on-one sessions offered, received training to co-facilitate the six group sessions with the interventionist, and is successfully self-managing his/her chronic pain.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: The control group will receive treatment as usual. The treatment as usual or control group refers to the standard of care that patients receive for their chronic pain. This standard of care allows patients to discuss chronic pain with their providers at their discretion. Although highly variable, providers can recommend and prescribe pharmacologic (e.g., opioid and other pain medication), non-pharmacologic (e.g., physical therapy, referral to psychology) approaches for pain. This study will not interfere in any way with usual care. No additional treatment will be provided to participants allocated to the control group.
Study: NCT02360748

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant based high protein food items
Description: Patients will add high protein plant based food items to their diet
Study: NCT04592497

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AF ablation
Description: Prospective, single-center, non-randomized, open label, two arm study. After informed consent, 60 consecutive subjects who are scheduled to undergo AF ablation will be enrolled in the study in two equally sized groups of 30 subjects each. One group will undergo the procedure with assistance THERMOCOOL SMARTTOUCH SF-5D QDOT system and the other with the standard Thermocool Smartouch SF system. Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months. Data will be anonymized by removing patient protected health information, only initials will be used.
Study: NCT04340765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluorocholine
Description: Dual phase 18F-fluorocholine PET/CT
Study: NCT01520337

Intervention type: DEVICE
Intervention: oral tablet dye for detection of polyps during colonoscopy
Description: oral tablet dye for improved detection of
Study: NCT02904785

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Waves

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Extracorporeal Shock Waves

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activities
Description: Patients receive instructions for physical activities for strengthening of femoral quadriceps and stretching of hamstring muscles.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physical activities
Description: Patients receive instructions for physical activities for strengthening of femoral quadriceps and stretching of hamstring muscles.
Study: NCT02895360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAL101553
Description: BAL101553 48-hour infusion on day 1, 8, and 15 of each 28-day cycle; oral capsule daily for one week during Cycle 2 (study days 15-21)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAL101553 at MTD
Description: BAL101553 48-hour infusion on day 1, 8, and 15 of each 28-day cycle; treatment with maximum tolerated dose (MTD)
Study: NCT03922152

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course radiotherapy
Description: An accelerated hypo-fractionation 2D-radiotherapy is delivered for palliation in patients with advanced esophageal cancer.
Study: NCT00131963

Intervention type: DRUG
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Intervention: doxorubicin
Description: Given IV

Intervention type: DRUG
Intervention: doxorubicin
Description: Given IV

Intervention type: DRUG
Intervention: paclitaxel
Description: Given IV
Study: NCT03502577

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-specific CAR-expressing T Lymphocytes
Description: Receive CAR T infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor LY3039478
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies
Study: NCT01765738

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICC (Cook, Bard)
Description: Comparison of antibiotic coated PICC vs. non-coated PICC

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICC (Cook, Bard)
Description: Comparison of antibiotic coated PICC vs. non-coated PICC
Study: NCT01114490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anacetrapib
Description: single dose administration of anacetrapib (MK0859) 100 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anacetrapib
Description: single dose administration of anacetrapib (MK0859) 100 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anacetrapib
Description: single dose administration of anacetrapib (MK0859) 100 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anacetrapib
Description: single dose administration of anacetrapib (MK0859) 100 mg oral tablet
Study: NCT02543099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: policosanol
Description: Patients will receive policosanol 20mg Qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will receive placebo 20mg Qd;
Study: NCT02325362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miglustat ; placebo
Description: For this 2 x 2 (2 periods /2 treatments) crossover design each patient will receive Miglustat during the first period (2 weeks), following by a wash out period(14 days (up to 4 weeks)), then Placebo during the second period (2 weeks). 30 days follow-up will be carried out after end-of-treatment of the second period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ; Miglustat
Description: For this 2 x 2 (2 periods /2 treatments) crossover design each patient will receive Placebo during the first period (2 weeks), following by wash out period (14 days (up to 4 weeks)), then Miglustat during the second period (2 weeks). 30 days follow-up will be carried out after end of treatment of the second period.
Study: NCT04155034

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic Cranial Irradiation
Description: Undergo PCI
Study: NCT03219177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education regarding indications for opioid use and side effects of opioid use after hand surgery
Description: Patients in the active education group will be given information pre-operatively on the current opioid epidemic, alternative pain management strategies that should be tried before proceeding to prescription opioid use, appropriate indications for opioid use, and side effects of opioids.This information will be reinforced by the research coordinator and nursing staff in the post-anesthesia care unit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care post-operative counseling
Description: Patients will receive standard of care post-operative counseling. They will not be given pre or post-operative opioid education.
Study: NCT00886353

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: APN01
Description: APN01, a physiological formulation of recombinant human Angiotensin Converting Enzyme 2 administrated i.v.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiological saline administrated i.v.
Study: NCT03178344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XCSITE100 Stimulator tACS
Description: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XCSITE100 Stimulator tACS
Description: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XCSITE100 Stimulator Sham
Description: The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XCSITE100 Stimulator Sham
Description: The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session.
Study: NCT04468230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Transdermal Patch
Description: Nicotine Treatment Condition
Study: NCT03017937

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q-collar
Description: capture ultrasound images at each pressure point
Study: NCT03540745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TES Treatment
Description: Device: Nexalin Based Trans-Cranial Electrical Stimulation The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current. Other Name: TES

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TES-SHAM Treatment
Description: Device: Nexalin Based Trans-Cranial Electrical Stimulation The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current. Other Name: TES
Study: NCT04225741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training group
Description: The single-session training lasted for approximately 40-45 minutes and was conducted in the training room of Sıtmapınarı family health center, as a suitable environment. The health belief model predicts the determinants of preventive health behaviors and explains inadequate participation in disease prevention and screening programs. Furthermore, this model not only explains behavior regarding screening, but also evaluates the cognitive factors that facilitate health-promoting behaviors.
Study: NCT03313141

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Volitional and non volitional respiratory tasks
Study: NCT00531726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS of Cg25

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DBS of Cg25
Study: NCT01855347

Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy
Description: NIRS Monitoring with four channels regional areas of the preterm infant, such as: Submandibular, Periumbilical, Abdominal (Spleen region) and infant thigh.
Study: NCT04700059

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual perinatal home visiting
Description: 10 perinatal home visits
Study: NCT00508495

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol (acetaminophen)
Description: Four 100 mL, 15 min IV infusions at six hour intervals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 1% solution
Description: Four 100 mL, 15 min IV infusions at six hour intervals

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride solution
Description: Four 100 mL, 15 min IV infusions at six hour intervals
Study: NCT04883060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: midline localizer
Description: a midline localizer device with a laser pointer is used to localize where the midline is likely to be located on the patient head prior to the surgery.
Study: NCT03005990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training group
Description: The conditioning period (24 weeks) of the exercise intervention was under the supervision of an exercise physiologist. The conditioning protocol included aerobic exercise sessions 3 times per week with 70-85% of maximal heart rate(max HR) for 30 mins and resistance sessions 3 times per week with an intensity of 80% of one-repetition maximum(1RM), 3 sets of 8 repetitions maximum. Each participant will measured the borg rating of perceived exertion scale and heart rate monitor during exercise. Exercise sessions were conducted in the afternoon (3-5 PM).
Study: NCT01951768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Garamycin Sponge (Gentamicin-Collagen sponge)
Description: Gentamicin Collagen Sponge: 5 × 5 cm in size containing Type I bovine collagen and 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic Antibiotic
Description: Antibiotics options per protocol:~Levofloxacin PO 750 mg q.24h or 500 mg q.12h Levofloxacin IV 750 mg q.24h or 500 mg q.12h Amoxicillin/clavulanate PO 500/125 mg q.12h. or q.8h Amoxicillin/clavulanate IV 1000/200 mg q.12h or q.8h Clindamycin PO 300 mg or 450 mg q.6h Clindamycin IV 600 mg q.8h or q.6h Linezolid PO 600 mg q.12h Linezolid IV 600 mg q.12h Metronidazole PO 400 mg or 500 mg q.8h or 500 mg q.6h Metronidazole IV 500 mg q.8h or q.6h Aztreonam IV 1 g or 2 g q.12h or q.8h Piperacillin/tazobactam IV 3000/375 mg q.6h or 4000/500 mg q.8h
Study: NCT01076790

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine infusion 1 mcg/kg in 10 minutes; thereafter 0.7 mcg/kg/h until 30 minutes has elapsed from skin incision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline infusion 1 mcg/kg in 10 minutes; thereafter 0.7 mcg/kg/h until 30 minutes has elapsed from skin incision.
Study: NCT02614612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib (200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib (300 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone or methylprednisolone (corticosteroids)
Description: All subjects will receive prednisone 2.5 mg/kg per day PO (or methylprednisolone 2 mg/kg IV daily) on Days 1 through 5. Subjects will be tapered as tolerated beginning on Day 6 to no less than 0.25 mg/kg per day PO (or methylprednisolone 0.2 mg/kg per day) by Day 28. After Day 28, corticosteroids should be tapered according to institutional guidelines to attain ≤ prednisone 0.2 mg/kg per day (or ≤ methylprednisolone 0.16 mg/kg per day) by Day 56.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone or methylprednisolone (corticosteroids)
Description: All subjects will receive prednisone 2.5 mg/kg per day PO (or methylprednisolone 2 mg/kg IV daily) on Days 1 through 5. Subjects will be tapered as tolerated beginning on Day 6 to no less than 0.25 mg/kg per day PO (or methylprednisolone 0.2 mg/kg per day) by Day 28. After Day 28, corticosteroids should be tapered according to institutional guidelines to attain ≤ prednisone 0.2 mg/kg per day (or ≤ methylprednisolone 0.16 mg/kg per day) by Day 56.
Study: NCT00301483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemoglobin-based oxygen carrier-201 (HBOC 201)
Description: HBOC-201 is an investigational solution of sterile, ultrapurified, glutaraldehyde polymerized, modified bovine hemoglobin (Hb) in a balanced electrolyte solution. HBOC-201 has an Hb concentration of 12-14g/dL. HBOC-201 is an isosmotic solution that is stable for at least 36 months at 2-30ºC. It requires no reconstitution and can be administered directly into a peripheral or central vein. Blood typing is not required because all other cellular components, including the RBC membranes that carry the blood group antigens, have been removed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard Therapy
Study: NCT00996502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Phase I:~* Cohort 1: 55mg/m2 of Docetaxel on Day 1 of the cycle~* Cohort 2: 65mg/m2 of Docetaxel on Day 1 of the cycle~* Cohort 3: 75mg/m2 of Docetaxel on Day 1 of the cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15mg/kg of Bevacizumab every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 200 mg of Erlotinib PO daily days 2-16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg of Prednisone PO bid
Study: NCT00302159

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Orally 75mg/m\^2 first day of radiation until completion. Restart 4 weeks post radiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Orally 25mg/kg/day twice a day concurrently with radiation therapy and temozolomide.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: External beam radiation Monday-Friday in 2 Gy fractions to 60 Gy total.
Study: NCT04477993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Janus Kinase Inhibitor (ruxolitinib)
Description: 5 mg P.O. b.i.d. for 14 days. Dose reduction will occur if neutrophils \< 500/mm3 or platelets \<50,000/mm3.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets P.O. b.i.d. for 14 days.
Study: NCT04187716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject
Description: For patients undergoing chemotherapy, ferinject 1000mg will be injected within 24 hours or 24 hours after day 1 of the next chemotherapy cycle.~Patients using targeted therapies can be dosed at any time after recognizing Hb 8.0-10.5g / dL and injecting 1000 mg of ferinject.

Intervention type: DRUG
Group type: OTHER
Intervention: Ferinject
Description: For patients undergoing chemotherapy, ferinject 1000mg will be injected within 24 hours or 24 hours after day 1 of the next chemotherapy cycle.~Patients using targeted therapies can be dosed at any time after recognizing Hb 8.0-10.5g / dL and injecting 1000 mg of ferinject.
Study: NCT00265408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Study: NCT02400203

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemp foods
Study: NCT02788318

Intervention type: OTHER
Intervention: Brain samples
Description: Collected in patients died

Intervention type: OTHER
Intervention: Brain samples
Description: Collected in patients died

Intervention type: OTHER
Intervention: Brain samples
Description: Collected in patients died

Intervention type: OTHER
Intervention: Skin samples
Description: Collected in patients died

Intervention type: OTHER
Intervention: Skin samples
Description: Collected in patients died

Intervention type: OTHER
Intervention: Skin samples
Description: Collected in patients died
Study: NCT01336205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-118
Description: 25 mg oral tablet once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: As prescribed by the investigator
Study: NCT00336817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myfortic
Description: Myfortic 360mg or 720 mg BID for 90 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CellCept
Description: CellCept 500mg or 1000mg BID for 90 days
Study: NCT01846403

Intervention type: DEVICE
Group type: OTHER
Intervention: Semi-quantitative urine pregnancy test
Study: NCT02813993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health educational video
Study: NCT03757871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser stimulation
Description: an acupuncture or placebo session will be performed 30 minutes before the fundus examination. This session will last 5 minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Laser stimulation
Description: an acupuncture or placebo session will be performed 30 minutes before the fundus examination. This session will last 5 minutes.
Study: NCT03707847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: 250mg, BID, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Capsule
Description: 50mg, QD, PO, d1-10，21days for one cycle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auto-HSCT
Description: Auto-HSCT will be performed with patients who have achieved CR or VGPR.
Study: NCT02561247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prismaflex HF20 CRRT Filter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prismaflex® System 7.10 and 7.20
Study: NCT00093977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa SF
Description: Frequency of dosing depends on frequency at randomization:~rHuEPO QW = darbepoetin alfa SF Q2W (dosing conversion table in protocol) rHuEPO biw or tiw = darbepoetin alfa SF QW (dosing conversion table in protocol) darbepoetin alfa RB = darbepoetin alfa SF at same dose and frequency PFS 10, 15, 20, 30, 40, 50, 60, 80, 100, 150, 200 or 300 mcg; Hb maintained between 11.0 - 13.0 g/dL
Study: NCT04091815

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Type of anaesthesia
Description: Two different types of anesthesia general vs combined (spinal and general)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Type of anaesthesia
Description: Two different types of anesthesia general vs combined (spinal and general)
Study: NCT05037890

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Margarine
Description: Intake of margarine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Margarine
Description: Intake of margarine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Margarine
Description: Intake of margarine
Study: NCT04598295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-01
Description: synbiotic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DS-01
Description: synbiotic